Surgeon Presentations to Highlight RxSight® Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
April 19 2022 - 3:30PM
(NASDAQ: RXST) -- RxSight, Inc., an
ophthalmic medical device company dedicated to improving the vision
of patients following cataract surgery, today announced that its
Light Adjustable Lens system, comprised of the RxSight Light
Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and
accessories, will be the subject of various surgeon presentations
at the annual meeting of the American Society of Cataract and
Refractive Surgery (ASCRS) in Washington D.C. on April 22-26,
2022.
The following are posters and papers accepted for
presentation:
Friday, April 22:
Evaluation of Clinical Outcomes after Implantation of an IOL
That Can Be Optimized with UV Light Compared to an Extended Depth
of Focus IOL. Poster presented by Neda Nikpoor, MD (12:55 p.m. EDT,
WEWCC).
Quantifying Post-Operative Satisfaction in Patients with
Intraocular Premium Lenses Relative to Their Pre-Operative
Lifestyle Questionnaire. Poster presented by Abhilash Guduru, MD
(2:40 p.m. EDT, WEWCC).
Saturday, April 23:
Descemet Membrane Endothelial Keratoplasty Combined with
Implantation of Light Adjustable Lens. Paper presented by David A.
Price, MD (1:30 p.m. EDT, WEWCC, Level 1, 143C).
Intraocular Lens Position of Light Adjustable Lens and Biometric
Changes: 1-Year Follow-up. Paper presented by Guglielmo Buonomo, MD
(1:30 p.m. EDT, WEWCC, Level 1, 144A).
Sunday, April 24:
Visual Outcomes of Patients Bilaterally Implanted with the Light
Adjustable Lens. Paper presented by Kerry D. Solomon, MD (10:51
a.m. EDT, WEWCC Level 1, 143A).
Evaluation of Clinical Outcomes After Implantation of an IOL
That Can Be Optimized with UV Light After Implantation. Paper
presented by Neda Nikpoor, MD (3:40 p.m. EDT, WEWCC Level 1,
143B).
Light Adjustable Intraocular Lens in Patients with Radial
Keratotomy Undergoing Cataract Surgery: A Case Series. Paper
presented by Amir Marvasti, MD (4:05 p.m. EDT, WEWCC Level 1,
143B).
Monday, April 25:
Evaluation of Near and Distance Visual Acuities After Bilateral
Implantation of an IOL That Can Be Optimized After Implantation.
Paper presented by T. Hunter Newsom, MD (4:03 p.m. EDT, WEWCC,
Level 1, 144A).
In addition, numerous surgeons will present their LAL experience
at the RxSight booth in the convention exhibit hall (Booth 509). A
schedule of these presentations, which are not affiliated with the
official ASCRS program, is available here and at the company’s
booth throughout ASCRS.
About RxSight, Inc.RxSight, Inc. is a
commercial-stage medical technology company dedicated to improving
the vision of patients following cataract surgery. The RxSight
Light Adjustable Lens system, comprised of the RxSight Light
Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and
accessories, is the first and only commercially available
intraocular lens (IOL) technology that enables doctors to customize
and optimize visual acuity for patients after cataract surgery. The
LAL now features ActivShield™ technology, a revolutionary UV
protection layer built into the lens. Additional information about
RxSight can be found at www.rxsight.com.
Forward-Looking StatementsThis press release
contains forward-looking statements, including the LAL’s
unparalleled ability to deliver customized, high quality vision for
patients, the ability for the RxSight system to expand premium
practice revenue for doctors, the Company’s momentum going into
2022, the Company’s projected revenue, gross margin and net loss
for 2022. Such statements relate to future events or our future
financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our
industry's actual results, levels of activity, performance or
achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied
or inferred by these forward-looking statements, and among other
things, our ability to maintain cash balances and successfully
commercialize or partner our product candidates currently under
development. Potential risks and uncertainties may also include the
continued efficacy and safety profile of our products as might be
suggested in presentations at the ASCRS meeting. In some cases, you
can identify forward-looking statements by terminology such as
"may," "will," "should," "could," "would," "expects," "plans,"
"intends," "anticipates," "believes," "estimates," "predicts,"
"projects," "potential," or "continue" or the negative of such
terms and other same terminology. These statements are only
predictions based on our current expectations and projections about
future events. You should not place undue reliance on these
statements. Actual events or results may differ materially. In
evaluating these statements, you should specifically consider
various factors. These and other factors may cause our actual
results to differ materially from any forward-looking statement. We
undertake no obligation to update any of the forward-looking
statements after the date of this press release to conform those
statements to reflect the occurrence of unanticipated events,
except as required by applicable law.
Investor Relations Contact:Philip Taylor
Gilmartin Group415.937.5406IR@rxsight.com
Company Contact:Shelley ThunenRxSight,
Inc.949-521-7830IR@rxsight.com
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jun 2024 to Jul 2024
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jul 2023 to Jul 2024